Alnylam Pharmace. sell dimontalban
Summary
This prediction ended on 04.09.22 with a price of €207.50. With a performance of -3.44%, the SELL prediction by dimontalban was trending in the right direction. dimontalban has 60% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | -9.541% | -9.541% | 22.849% |
iShares Core DAX® | -1.215% | 4.788% | 16.604% |
iShares Nasdaq 100 | -1.911% | 1.109% | 19.364% |
iShares Nikkei 225® | -3.171% | 5.626% | 10.519% |
iShares S&P 500 | -1.029% | 1.792% | 20.514% |
According to dimontalban what are the pros and cons of Alnylam Pharmace. for the foreseeable future?
Pros
Cons
Comments by dimontalban for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.